Geoffrey I. Shapiro

Also affiliated with Harvard University, Dana-Farber Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

8in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 8 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

(2023)10.1158/1078-0432.c.6532290.v1

Top 100%

0DataRank

Top 100%0 citations

Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C. Cantley +10 more

Papers

Driven by 77 papers — median percentile 0. Top paper: “Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial”.

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30180-7

N/A

5.1DataRank · unranked

233 citations

Su-Chun Cheng, Andrea E. Wahner Hendrickson, Richard T. Penson, Susan Schumer, L. Austin Doyle +19 more

Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open‐label, dose escalation study

International Journal of Cancer(2021)10.1002/ijc.33861

N/A

1.9DataRank · unranked

62 citations

Jean‐Yves Blay, Irene García, Johann S. De Bono, Christophe Le Tourneau, Víctor Moreno +25 more

Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3045

N/A

1.5DataRank · unranked

64 citations

Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C. Cantley +10 more

Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2007

N/A

0.965DataRank · unranked

32 citations

Arun S. Singh, Stephen P. Anthony, Mike Sterba, Chao Zhang, John H. Healey +19 more

Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity

Cancer Research(2024)10.1158/0008-5472.can-23-4007

N/A

0.679DataRank · unranked

24 citations

Ozge Somuncu, Ramya Ravindranathan, Sirisha Mukkavalli, David B. Martignetti, Huy Nguyen +11 more

A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2005

N/A

0.503DataRank · unranked

14 citations

Hanrong Feng, Kalindi Parmar, Junning Wang, Kevin S. Kapner, Bose Kochupurakkal +23 more

A phase 2 study of berzosertib (M6620) in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5034

N/A

0.461DataRank · unranked

8 citations

Wanling Xie, Edmund Folefac, Daniel Lee, Mamta Parikh, David J. Einstein +12 more

Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study

ESMO Open(2022)10.1016/j.esmoop.2022.100571

N/A

0.427DataRank · unranked

11 citations

Barbara Pistilli, Irene Braña, Geoffrey I. Shapiro, José Trigo, Víctor Moreno +13 more

CTEP 9557: A dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF mutant solid tumors.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3609

N/A

0.293DataRank · unranked

4 citations

James M. Cleary, Justine V. Cohen, Donald P. Lawrence, Elizabeth I. Buchbinder, Anita Giobbie‐Hurder +11 more

A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps5597

N/A

0DataRank · unranked

3 citations

Wanling Xie, Mamta Parikh, Daniel Lee, Elizabeth R. Kessler, David J. Einstein +8 more

A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.tps252

N/A

0DataRank · unranked

0 citations

Wanling Xie, Mamta Parikh, Daniel Lee, Elizabeth R. Kessler, David J. Einstein +8 more

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

UNC Libraries(2020)10.17615/j6a6-ag16

N/A

0DataRank · unranked

0 citations

Jacob B. Reibel, Jeremy H. Tchaicha, Julián Carretero, Pasi A. Jänne, Mohit Butaney +22 more

Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer

Cell(2021)10.1016/j.cell.2021.11.017

N/A

0DataRank · unranked

596 citations

Peter Winter, Andrew W. Navia, Hannah L. Williams, Alan DenAdel, Kristen E. Lowder +42 more

EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer

Nature Cancer(2021)10.1038/s43018-021-00185-w

N/A

0DataRank · unranked

241 citations

Anjali V. Sheahan, Deborah L. Burkhart, Sylvan C. Baca, Nadia Boufaied, Yin Liu +32 more

FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma

Cancer Discovery(2021)10.1158/2159-8290.cd-20-1669

N/A

0DataRank · unranked

109 citations

Srivatsan Raghavan, Qibiao Wu, Yvonne Y. Li, Liam F. Spurr, Hersh Gupta +35 more

A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

Nature Communications(2021)10.1038/s41467-021-25904-w

N/A

0DataRank · unranked

69 citations

Alexandre André Balieiro Anastácio da Costa, D. Gulhan, Elizabeth K. Lee, Su-Chun Cheng, Andrea E. Wahner Hendrickson +14 more

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

UNC Libraries(2021)10.17615/6prg-vp52

N/A

0DataRank · unranked

37 citations

Hongbin Ji, Norman E. Sharpless, Pasi A. Jänne, Mitchell Albert, Daniel G. Tenen +16 more

Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4073

N/A

0DataRank · unranked

35 citations

Yvonne Y. Li, Liam F. Spurr, Atul B. Shinagare, Ritika Abhyankar, Emma Reilly +25 more

Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-1367

N/A

0DataRank · unranked

14 citations

Brian M. Wolpin, Stephanie K. Dougan, Srivatsan Raghavan, Harshabad Singh, Brandon M. Huffman +6 more

Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report

Journal of Gastrointestinal Oncology(2021)10.21037/jgo-21-197

N/A

0DataRank · unranked

4 citations

Brian M. Wolpin, Ilana S. Warsofsky, David P. Ryan, Kimberly Perez, Osama E. Rahma +7 more

NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.11506

N/A

0DataRank · unranked

11 citations

Jacob B. Allred, Katherine Gano, Suzanne George, Steven Attia, Melissa Burgess +15 more

STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA -associated breast cancer

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.01.26.428337

N/A

0DataRank · unranked

5 citations

Heta Jadhav, Aditi Kothari, Renyan Liu, Jennifer L. Guerriero, Geoffrey I. Shapiro +1 more

Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53 -Mutant Cancers

Cancer Research(2022)10.1158/0008-5472.can-22-1124

N/A

0DataRank · unranked

62 citations

Arindam Bose, Wei-Chih Tsai, Carter Grochala, Huy Nguyen, Jia Zhou +8 more

Report of the First International Symposium on NUT Carcinoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0591

N/A

0DataRank · unranked

55 citations

Michael L. Cheng, Glenn J. Hanna, Steven G. DuBois, Nicole G. Chau, Christine L. Hann +18 more

MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer

Molecular Cancer Research(2022)10.1158/1541-7786.mcr-22-0772

N/A

0DataRank · unranked

36 citations

Yoshihiro Morimoto, Atsushi Fushimi, Rehan Ahmad, Atrayee Bhattacharya, Tatsuaki Daimon +15 more

STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer

npj Breast Cancer(2022)10.1038/s41523-022-00471-5

N/A

0DataRank · unranked

35 citations

Heta Jadhav, Aditi Kothari, Renyan Liu, Gerburg M. Wulf, Jennifer L. Guerriero +2 more

Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes

JCO Precision Oncology(2022)10.1200/po.21.00456

N/A

0DataRank · unranked

30 citations

Erika Hamilton, Todd M. Bauer, Ecaterina E. Dumbrava, Rinath Jeselsohn, Aaron Enke +6 more

NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3012

N/A

0DataRank · unranked

13 citations

Karen Kelly, Saiama N. Waqar, Elizabeth J. Davis, Geoffrey I. Shapiro, Patricia LoRusso +7 more

Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3313

N/A

0DataRank · unranked

80 citations

Michael A. Postow, Bartosz Chmielowski, Ryan J. Sullivan, Amita Patnaik, Ezra E.W. Cohen +12 more

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3334

N/A

0DataRank · unranked

59 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3930

N/A

0DataRank · unranked

47 citations

Rachel B. Keller, Kevin S. Kapner, Julien Dilly, Srivatsan Raghavan, Chen Yuan +27 more

The BRD4–NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma

Cancer Research(2023)10.1158/0008-5472.can-23-2545

N/A

0DataRank · unranked

39 citations

Julianna Huang, Luke Wojenski, Yeying Huang, Prafulla C. Gokhale, Brittaney A. Leeper +14 more

PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer

The Journal of Experimental Medicine(2023)10.1084/jem.20220729

N/A

0DataRank · unranked

34 citations

Ana C. Garrido-Castro, Patrick J. Lenehan, Naïma Böllenrücher, Courtney T. Stump, Michael Dougan +5 more

RETRACTED ARTICLE: Polymerase θ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer

Nature Communications(2023)10.1038/s41467-023-37096-6

N/A

0DataRank · unranked

22 citations

Heta Jadhav, Constantia Pantelidou, Tin Phan, Carter Grochala, Anita K. Mehta +9 more

EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes

Cancer Research(2023)10.1158/0008-5472.can-23-1475

N/A

0DataRank · unranked

17 citations

R. Taylor Durall, Nhi M. Luong, Hans J. Hertzler, Julianna Huang, Prafulla C. Gokhale +21 more

Initial Chemotherapy for Locally Advanced and Metastatic NUT Carcinoma

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.12.022

N/A

0DataRank · unranked

14 citations

Michelle Sanchez, Elinton Lee, Hans J. Hertzler, Nhi M. Luong, Emanuele Mazzola +17 more

Exploring pharmacokinetics of talazoparib in ABCB1/ABCG2-deficient mice using a novel UHPLC-MS/MS method

Heliyon(2023)10.1016/j.heliyon.2023.e20972

N/A

0DataRank · unranked

3 citations

Dominique A. Garrison, Eric D. Eisenmann, Kalindi Parmar, Geoffrey I. Shapiro, Michelle A. Rudek +3 more

Novel BRD2::NUTM1 Fusion in NUT Carcinoma With Exceptional Response to Chemotherapy: A Case Report

JTO Clinical and Research Reports(2023)10.1016/j.jtocrr.2023.100625

N/A

0DataRank · unranked

2 citations

Justin J. Kim, Yeying Huang, R. Taylor Durall, Simone Becker, Stephanie Canty +6 more

664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors

Annals of Oncology(2023)10.1016/j.annonc.2023.09.1850

N/A

0DataRank · unranked

1 citations

T. Khanh, James M. Cleary, Aparna R. Parikh, Oladapo Yeku, Colin D. Weekes +13 more

Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5512

N/A

0DataRank · unranked

6 citations

Elizabeth Katherine Lee, Su–Chun Cheng, Alexandre André Balieiro Anastácio da Costa, Andrea E. Wahner Hendrickson, D. Gulhan +14 more

A phase 2 study of the WEE1 inhibitor AZD1775 in SETD2-deficient advanced solid tumor malignancies.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3104

N/A

0DataRank · unranked

3 citations

W. Kimryn Rathmell, Geoffrey I. Shapiro, Jordi Rodon Ahnert, Devalingam Mahalingam, Nikolaos A. Trikalinos +9 more

A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps5110

N/A

0DataRank · unranked

2 citations

Wanling Xie, Archana Ajmera, Arlene Araneta, Christina Jamieson, Edmund Folefac +14 more

EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genes

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.08.15.553204

N/A

0DataRank · unranked

2 citations

R. Taylor Durall, Nhi M. Luong, Hans J. Hertzler, Julianna Huang, Prafulla C. Gokhale +21 more

885 Characterization of the tumor microenvironment in advanced breast cancer patients treated with talazoparib followed by combination of talazoparib and avelumab

Regular and Young Investigator Award Abstracts(2023)10.1136/jitc-2023-sitc2023.0885

N/A

0DataRank · unranked

1 citations

Filipa Lynce, Xue Geng, Edward T. Richardson, Candace Mainor, Mei Wei +14 more

Data from Transcriptional Profiling Identifies Cyclin D1 as a Critical Downstream Effector of Mutant Epidermal Growth Factor Receptor Signaling

(2023)10.1158/0008-5472.c.6495248

N/A

0DataRank · unranked

0 citations

Takeshi Shimamura, Stefano Monti, Ulrich Steidl, Christopher J. Hetherington, April M. Lowell +6 more

Data from Transcriptional Profiling Identifies Cyclin D1 as a Critical Downstream Effector of Mutant Epidermal Growth Factor Receptor Signaling

(2023)10.1158/0008-5472.c.6495248.v1

N/A

0DataRank · unranked

0 citations

Takeshi Shimamura, Stefano Monti, Ulrich Steidl, Christopher J. Hetherington, April M. Lowell +6 more

Data from Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

(2023)10.1158/1078-0432.c.6532290.v1

Top 100%

0DataRank

Top 100%0 citations

Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C. Cantley +10 more

Data from Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer

(2023)10.1158/1078-0432.c.6532290

Top 100%

0DataRank

Top 100%0 citations

Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann, Lewis C. Cantley +10 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210.v1

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

Data from Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions

(2023)10.1158/1078-0432.c.6530721.v1

Top 100%

0DataRank

Top 100%0 citations

Yvonne Y. Li, Liam F. Spurr, Atul B. Shinagare, Ritika Abhyankar, Emma C. Reilly +25 more

Data from Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer

(2023)10.1158/1078-0432.c.6530060.v1

Top 100%

0DataRank

Top 100%0 citations

Tianyu Li, Tuulia Vallius, Jennifer L. Guerriero, Nabihah Tayob, Bose Kochupurakkal +17 more

Data from Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer

(2023)10.1158/1078-0432.c.6530060

Top 100%

0DataRank

Top 100%0 citations

Tianyu Li, Tuulia Vallius, Jennifer L. Guerriero, Nabihah Tayob, Bose Kochupurakkal +17 more

Data from National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)

(2023)10.1158/1078-0432.c.6533210.v2

Top 100%

0DataRank

Top 100%0 citations

James M. Ford, Peter J. O’Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin +18 more

982 Immune mediated mechanisms of PARPi resistance in BRCA1-associated triple negative breast cancer (TNBC)

Regular and Young Investigator Award Abstracts(2023)10.1136/jitc-2023-sitc2023.0982

N/A

0DataRank · unranked

0 citations

Anita K. Mehta, Madeline G Townsend, Madisson Oliwa, Kelly F Zheng, Patrice A. Lee +6 more

Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-3135

N/A

0DataRank · unranked

36 citations

T. Khanh, Jeong Eun Kim, James M. Cleary, Aparna R. Parikh, Oladapo Yeku +26 more

Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-2975

N/A

0DataRank · unranked

35 citations

Agostina Nardone, Douglas Russo, Zsuzsanna Nagy, Capucine Héraud, Albert Grinshpun +26 more

PARG inhibitor sensitivity correlates with accumulation of single-stranded DNA gaps in preclinical models of ovarian cancer

Proceedings of the National Academy of Sciences(2024)10.1073/pnas.2413954121

N/A

0DataRank · unranked

29 citations

Ozge Somuncu, Alexandre André Balieiro Anastácio da Costa, Sirisha Mukkavalli, Benjamin P. Lamarre, Huy Nguyen +8 more

Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations

Molecular Cancer Therapeutics(2024)10.1158/1535-7163.mct-23-0471

N/A

0DataRank · unranked

21 citations

Michael W. Lloyd, Soner Koc, Yvonne A. Evrard, Lisa M. McShane, Michael T. Lewis +29 more

A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer

ESMO Open(2025)10.1016/j.esmoop.2025.104536

N/A

0DataRank · unranked

60 citations

Martin H. Voss, Hussein A. Tawbi, Michael S. Gordon, Scott S. Tykodi, Elaine T. Lam +13 more

Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2024-010430

N/A

0DataRank · unranked

14 citations

Noah Graham, Lestat R. Ali, Christina I. Herold, Jennifer Desrosiers, Khanh Do +13 more

Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects

Cancer Discovery(2025)10.1158/2159-8290.cd-24-1500

N/A

0DataRank · unranked

6 citations

David S.P. Tan, Anastasios Stathis, Geoffrey I. Shapiro, Satoru Iwasa, Markus Joerger +17 more

Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphoma

Journal of Clinical Investigation(2025)10.1172/jci193006

N/A

0DataRank · unranked

6 citations

Shuhei Asada, Guangli Zhu, Yuna Hirohashi, Lisa A. Moreau, Divya Iyer +15 more

MUC1-C dependency in drug resistant HR+/HER2− breast cancer identifies a new target for antibody-drug conjugate treatment

npj Breast Cancer(2025)10.1038/s41523-025-00751-w

N/A

0DataRank · unranked

6 citations

Atrayee Bhattacharya, Hiroki Ozawa, Naoki Haratake, Keisuke Shigeta, Atsushi Fushimi +16 more

Disruption of Microhomology-mediated End-joining in Ewing Sarcoma

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.05.06.651696

N/A

0DataRank · unranked

2 citations

Guangli Zhu, Jithma P. Abeykoon, Yutaro Tanaka, Huy Tien Nguyen, Yuna Hirohashi +14 more

AXALAP: Phase Ib study of axatilimab in combination with olaparib in BRCA1/2 and PALB2 -associated metastatic HER2-negative breast cancer (BC).

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.tps1143

N/A

0DataRank · unranked

0 citations

Adela Rodríguez Hernandez, Siddhartha Yadav, Ryan Buehler, Grace Augdahl, Tasnim Rahman +9 more

Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies

Clinical Lung Cancer(2025)10.1016/j.cllc.2025.09.009

N/A

0DataRank · unranked

0 citations

Leena Gandhi, Vignesh Ravichandran, Benjamin Besse, Julien Mazières, Geoffrey I. Shapiro +20 more

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

Annals of Oncology(2020)10.1016/j.annonc.2020.02.008

N/A

0DataRank · unranked

157 citations

Ofir Cohen, Bose Kochupurakkal, D. Kim, Connor E. Dunn, Jorge Buendia +20 more

Defective Microhomology-Mediated End-joining in SMARCB1-Deficient Tumors

bioRxiv (Cold Spring Harbor Laboratory)(2025)10.1101/2025.11.20.689563

N/A

0DataRank · unranked

0 citations

Shuhei Asada, Huy Nguyen, Yuna Hirohashi, Lifang Sun, Avneesh Saravanapavan +4 more

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Nature Medicine(2020)10.1038/s41591-019-0716-8

N/A

0DataRank · unranked

395 citations

Jeffrey W. Clark, Jared Weiss, Sai‐Hong Ignatius Ou, D. Ross Camidge, Benjamin Solomon +16 more

Biomarker-Guided Development of DNA Repair Inhibitors

Molecular Cell(2020)10.1016/j.molcel.2020.04.035

N/A

0DataRank · unranked

230 citations

Andrew J. Aguirre, Geoffrey I. Shapiro, Alan D. D’Andrea, James M. Cleary

Cooperation of the ATM and Fanconi Anemia/BRCA Pathways in Double-Strand Break End Resection

Cell Reports(2020)10.1016/j.celrep.2020.01.052

N/A

0DataRank · unranked

85 citations

Connor E. Dunn, Wenxu Chen, Bose Kochupurakkal, Huy Nguyen, Lisa A. Moreau +5 more

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-4084

N/A

0DataRank · unranked

45 citations

Ryan D. Gentzler, Sarah Clifford, Jill Kolesar, Alona Muzikansky, Eric B. Haura +15 more

CHK1 Inhibitor Blocks Phosphorylation of FAM122A and Promotes Replication Stress

Molecular Cell(2020)10.1016/j.molcel.2020.10.008

N/A

0DataRank · unranked

56 citations

David Kozono, Peter Deraska, Timothy B. Branigan, Connor E. Dunn, Xiao-Feng Zheng +7 more

Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-3089

N/A

0DataRank · unranked

51 citations

Tianyu Li, Tuulia Vallius, Jennifer L. Guerriero, Nabihah Tayob, Bose Kochupurakkal +17 more

Polymerase Theta Inhibition Kills Homologous Recombination Deficient Tumors

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.05.23.111658

N/A

0DataRank · unranked

17 citations

Camille Gelot, Constantia Pantelidou, Adam Y. Li, Hatice Yücel, Rachel E. Davis +9 more

Randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.111

N/A

0DataRank · unranked

6 citations

Rana R. McKay, Mary‐Ellen Taplin, Nancy B. Davis, Paul Monk, Leonard J. Appleman +14 more

Geoffrey I. Shapiro

Indexed papers

Top data-sharing exemplar

Papers